Apr 08, 2020
CLS Therapeutics will be presenting at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

NEW YORK, NY /  April 08, 2020 / CLS Therapeutics, a privately held anticancer gene therapy platform company addressing a novel therapeutic target, announces presentation at the upcoming 2020 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting that will be held from April 29 to May 2, 2019 that is planned to be held May 12 – May 15, 2020, at the Hynes Convention Center in Boston, USA.

A poster presentation named “First-In-Class AAV-Based Gene Therapy for Pancreatic Cancer and Other Tumors Based on the Destruction of Cell-Free DNA with Vector-Delivered DNase I” will showcase CLS’ data for the use of their CLS-014 drug candidate. CLS has identified a new therapeutic target (blood tumor- and neutrophils- derived cell-free DNA) for the successful anticancer therapy for multiple cancers and their initial indication is pancreatic cancer. Thus,  CLS revolutionizes cancer therapy, since the proposed target was shown to play a primary role in the failure of existing anticancer therapies (and has been independently confirmed by leading universities and research groups). The Company uses smart AAV technology for the delivery of gene to the  liver, after which, hepatocytes in a 48 hours start to produce recombinant human enzyme that destroys this cell-free DNA.

The data that will be presented is exemplifies how CLS’ cutting-edge gene therapy capabilities can be leveraged to potentiate first-line chemotherapy, decrease primary tumor growth and prevent metastases formation in pancreatic cancer models. Furthermore, Dr. Tetz, MD, PhD., Chief Executive Officer of CLS Therapeutics, will be participating in the Scientific Symposiums.

Poster presentation details:

First-In-Class AAV-Based Gene Therapy for Pancreatic Cancer and Other Tumors Based on the Destruction of Cell-Free DNA with Vector-Delivered DNase I

George Tetz1, MD, PhD, Casey A Maguire3, PhD, Allan Tsung MD, Dmitry Genkin1 MD, Victor Tetz2 MD, PhD

1CLS Therapeutics Institute, New York, NY, 10013 USA

2Human Microbiological Institute, New York, NY, 10013 USA

 3Molecular Neurogenetics Unit, Massachusetts General Hospital, Harvard Medical

 4Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA

Thursday May 14, 2020 5:30 PM – 6:30 PM

Session Title: Cancer – Targeted Gene and Cell Therapy

Room: Exhibit Hall C & D

Final abstract number: 1178


Abstracts will be also available on the ASGCT website. The poster presentations to be presented at the 2020 ASGCT Annual Meeting will be available on the CLS Therapeutics website after  May 14, 2020.

Investor/Media Contact

Jenene Thomas Communications LLC
Jenene Thomas
(908) 938-1475

Aug 12, 2020

NEW YORK, NY /  July, 2020 / CLS Therapeutics, a preclinical-stage anticancer gene therapy platform company developing novel medicines to bring the curative power of cell-free DNA destruction to patients with tumors, presented preclinical data at the annual meeting of the American Society of Clinical Oncology (ASCO).

May 10, 2019

CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “TRANSFORMATIVE ANTICANCER GENE THERAPY PLATFORM ADDRESSING A NOVEL THERAPEUTIC TARGET” at the Targeting Tumor Heterogeneity Conference organized by the New York Academy of Sciences May 8, 2019, in New York, New York.

Mar 29, 2019

NEW YORK, March 29, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class-AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Cancer Metabolism and Signaling” being held on May 9, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed ) encoding DNase I of the treatment of pancreatic cancer animal model.